Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive product and pricing, industry trends and product initiatives including products in the development stage, which may not achieve scientific objectives or meet stringent regulatory requirements. Forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are based on currently available information, with management's current assumptions, expectations, and projections about future events. While management believes its assumptions, expectations, and projections are reasonable in view of currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's the actual results may differ materially from those discussed during this webcast for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the company's Form 10-K for the year 2021, which was filed March 11, 2022 and its other filings with the SEC, which are available on the Investor Relations section of Jaguar's website. Except as required by law, Jaguar undertakes no obligation to update or revise any forward-looking statements contained in this presentation to reflect new information, future events, or otherwise. Additionally, please note that the company's supplements its condensed consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA, and non-GAAP recurring EBITDA. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which company management assesses and operates the business. These non-GAAP financial measures should not be viewed in isolation or as a substitute for GAAP net sales and GAAP net loss and are not substitute for/or superior to measures [our] [ph] financial performance and the conformity with GAAP. Today's conference is being recorded. At this time, it is my pleasure to turn the call over to Lisa Conte, Jaguar Health's Founder, President, and Chief Executive Officer. The floor is yours Lisa.

Thank you. That’s quite a mouthful to start with. Welcome all, as you just heard, my name is Lisa Conte, and I am the Founder, President, and CEO of Jaguar Health and our wholly-owned subsidiary in the United States Napo Pharmaceuticals. I am also Chairman of the Board of Napo Therapeutics, the corporation we established in Milan, Italy last year to which we granted an exclusive license to crofelemer in Europe, and I'll be speaking about that more later. But I'm going to begin today with the key top line results for the second quarter of 2022. Prescription product net revenue of $2.9 million, representing an approximate 12% increase over Q1 2022, a quarter-over-quarter calculation, and an approximate 644% increase over Q2 last year 2021, a year-over-year calculation. This is the fourth consecutive quarter of growth in Mytesi net revenue and we are quite pleased with the growth trajectory of our current prescription drug business and as you'll hear, quite excited about the late stage pipeline opportunities that we feel will be transformative in the value creation and value recognition for all our stakeholders, including patients and shareholders. I'll continue with a few brief updates and then Carol Lizak, Jaguar's Chief Financial Officer will provide a recap of the key financial results for the second quarter of 2022. After Carol speaks, we’ll hear from Ian Wendt, Jaguar’s Chief Commercial Officer. Ian Wendt will speak to updates on Mytesi related commercial initiatives to continue to educate and serve the HIV community. The activities that will serve future pipeline indications for a crofelemer and about ongoing commercial efforts underway for Canalevia-CA1, our prescription drug to the treatment of chemotherapy induced diarrhea, which I'll refer to as CID, chemotherapy-induced diarrhea, in dogs that has been conditionally approved by the FDA and became commercially…

Thank you, Lisa, and thank you all for joining our webcast today. I'll begin my review of our financials for the second quarter of 2022. Mytesi net revenues during the second quarter of 2022 was approximately $2.8 million and about $2.6 million in the first quarter of 2022, an increase of approximately $200,000 or 10% quarter-over-quarter, and an increase of 644% over Mytesi net revenues in the second quarter of 2021, which totaled about 400,000. Mytesi prescription volume, the metric the company believes to be the best indicator of growth in patient demand, increased 8.2% in the second quarter of 2022 over the first quarter of 2022. Prescription volume differs from invoice sales volume, which reflects among other factors, varying buying patterns among specialty pharmacies in the closed network as they manage their inventory levels. Mytesi gross revenue, a non-GAAP measure, was approximately 3.7 million in the second quarter of 2022 and 3.4 in the first quarter of 2022, representing an increase of approximately $300,000 or 9% quarter-over-quarter, and a decrease of approximately 24% over Mytesi gross revenue in the second quarter of 2021, which totaled approximately 4.9 million. As Lisa mentioned, Canalevia-CA1 became commercially available to veterinarians across the U.S. at the end of April 2022. Canalevia-CA1 net and gross revenue during the second quarter of 2022 were $87,400. Non-GAAP EBITDA for the second quarter of 2022 and the second quarter of 2021 was a net loss of $5.4 million and $10.8 million, respectively. For the second quarter of 2022, the loss from operations was $6.3 million, compared to a loss of $11.6 million in the second quarter of 2021, a decrease of $5.3 million quarter-over-quarter. For the second quarter of 2022, the net loss attributable to common shareholders was approximately $9.4 million, compared to a net loss of $14.1 million in the second quarter of 2021, a decrease of approximately $4.7 million quarter-over-quarter and in addition to the loss from operations, interest expense increased by $500,000 from $2 million in the three months ended June 30, 2021. The [2.5 million] [ph] for the same period in 2022. That's primarily due to the interest from the royalty and note agreement. And the change in fair value of financial instruments and hybrid instruments designated as fair value options losses increased 1.2 million from a loss of 500,000 in the three months ended June 30, 2021 through a gain of $700,000 for the same period in 2022. Other expense increased by $1.1 million from $200,000 in the three months ended June 30, 2021, to 1.1 million for the same period in 2022, due to the foreign currency transactions. That concludes my recap of high level financials for the second quarter of 2022. I will now hand the discussion over to Ian Wendt, our Chief Commercial Officer.

Thank you, Carol, and good morning to all. As Carol stated, Mytesi total prescription volume, the metric we believe to be the best indicator of patient demand increased 8.2% in the second quarter of 2022 over the first quarter of 2022. As previously announced, the transition we completed this past January to a closed network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs, as well as a higher average net price. In fact, I'm very pleased to report that we significantly outperformed the industry gross to net average in the second quarter of 2022 as we did in both of the two previous quarters for sales of our human prescription product. This improvement in our [GTN] [ph] was largely as a result of the efficiencies realized by the transition to a closed network of specialty pharmacies. And as Lisa mentioned, Q2 2022 is the fourth consecutive quarter of growth in Mytesi net revenue, which we're also very pleased about. A key component of the company's market access strategy, our initiative to transition to a closed network of specialty pharmacies is intended to help remove access barriers for patients prescribed Mytesi and include services such as a higher level of support for prior authorizations, appeals, adherence counseling, and home delivery options. While patients often visit retail pharmacies for short-term or uncomplicated medical needs, specialty pharmacies focus primarily on serving patients with complex and chronic medical conditions like HIV. Importantly, this transition allowed us to begin utilizing sales and prescription data directly provided by our network of specialty pharmacies to more accurately track prescription volume and the patient journey rather than rely on a third party provider of estimated data for these important performance metrics. This also assists in the preparation of our U.S. commercial distribution network for…

Thanks, Ian. Thanks, Carol. We at Jaguar, Napo, and Napo Thera are energized about all of our important initiatives underway in 2022 and beyond. I would also like to mention that as we announced this past Friday, Jaguar received formal notice on August 18 that the listing qualification status of the NASDAQ soft market has granted the company an additional 180-day grace period through February 13, 2023 to gain compliance with the $1 bid price requirement for continued listing on the NASDAQ capital market. We are pleased to have obtained additional time from NASDAQ to evidence compliance with the bid price requirement. And as we seek to regain compliance with this rule, we are laser focused on our two late stage clinical events in the next approximate 6 months to 12 months that we expect to be transformational in terms of value creation and recognition for the company. We did file a preliminary proxy on Friday, August 19 for a special meeting of the shareholders of Jaguar. As noted in the proxy resolutions, we are not taking a reverse split of the Jaguar shares. We'll now open the floor for written questions that have come in, and I will move to those now. Can repeat the question. There aren't a lot, but there is a couple here. One of them was is, during the past slide presentation, you mentioned that there would be a [color voucher filing] [ph] in the first half of the second quarter of 2022, when is the filing of the voucher for color going to happen? So, I think that is a bit of a misunderstanding. So, the voucher for the color [indiscernible], the tropical disease priority view voucher, it's something that is granted by the FDA upon FDA approval for the topical disease. So, another…

Once again, ladies and gentlemen, this does conclude your webcast for today. Thank you for your participation and you may now disconnect. End of Q&A: